ArticleBiomolecules2025
The Possible Role of Neurofilament Light Chain as a Serum Biomarker in Anorexia Nervosa: Clinical Implications.
Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurofilament light chain (NfL) is a well-established biomarker of neuroaxonal damage, detectable in serum through immunoassays. Its potential relevance in psychiatric conditions, including anorexia nervosa (AN), is currently under investigation. This study aims to quantify serum NfL levels in individuals with AN, evaluate their correlation with autoantibodies detection, and critically examine the specificity of NfL as a biomarker in this context.
methodsA total of 100 participants were enrolled, comprising 50 individuals diagnosed with AN and 50 age-matched, normal-weight controls. Serum concentrations of NfL and immunoglobulin G (IgG) antibodies reactive to hypothalamic antigens were measured using validated immunoassay techniques.
resultsSerum NfL concentrations were markedly higher in the AN group compared to healthy controls. Interestingly, NfL levels tended to decrease with longer disease duration and with the recovery of body mass index (BMI), indicating a possible association between clinical improvement and reduced neuroaxonal damage. Furthermore, the results confirmed the presence of anti-hypothalamic autoantibodies and revealed a positive correlation between their levels and serum NfL concentrations.
conclusionsClinical remission in AN appears to be linked to a decrease in both markers neuronal damage and hypothalamic autoimmunity. However, as elevated serum NfL is observed across a spectrum of neurological and psychiatric disorders, its specificity as a biomarker for AN should be further investigated. While NfL may reflect neuroaxonal injury in AN, its interpretation should be contextualized within a broader clinical and immunological framework.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.